INTRODUCTION

Infectious and inflammatory diseases of the pharynx remain the focus of attention of physicians of many specialties due to their high prevalence and social significance.

MATERIAL AND METHODS

The main group (n=30, mean age 68.9±5.6 years) was prescribed Dorithricin for resorption, 1 tablet every 3 hours, no more than 6 tablets per day for 6 days. The control group (n=30, mean age 68.3±4.7 years) was recommended treatment with antiviral and antipyretic agents.

RESULTS

By the 2nd visit, 16.7% of elderly patients experienced complete relief of sore throat, and no cases of high-intensity sore throat were recorded. By the 3rd day of treatment, the proportion of such patients increased significantly, amounting to 43.3%, and by the end of treatment, 96.7% of patients taking Dorithricin had no sore throat. The most significant changes during treatment were noted in relation to such additional symptoms as discomfort when swallowing and dysphagia. When assessing the pharyngoscopic picture, statistically significant differences were noted between the groups by the 2nd visit in relation to hyperemia of the oropharyngeal mucosa (p=0.048), the severity of edema of the oropharyngeal mucosa (p=0.043). Patients who received Dorithricin rated their satisfaction with the treatment as satisfied and extremely satisfied in 33.3% and 66.7%, the assessment of doctors was comparable.

CONCLUSION

This study may contribute to the confidence of physicians in prescribing the complex drug Dorithricin, which includes substances that affect all key components of the pathogenesis of acute tonsillopharyngitis in elderly patients and increase patient satisfaction and expectations.